Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet …, 2019 - thelancet.com
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …
被引用次数：196 相关文章

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet …, 2019 - folia.unifr.ch
METHODS RISE-IIP was a double-blind, randomised, placebo-controlled study done at 65
pulmonary hypertension and interstitial lung disease centres in 19 countries to evaluate the …

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet Respiratory …, 2019 - Elsevier
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet …, 2019 - thelancet.com
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet …, 2019 - mpgjournal.mpg.es
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

SD Nathan, J Behr, HR Collard… - Lancet …, 2019 - epub.ub.uni-muenchen.de
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …

[引用][C] Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet Respiratory …, 2019 - cir.nii.ac.jp
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP):
a randomised, placebo-controlled phase 2b study | CiNii Research CiNii 国立情報学研究所 …

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet. Respiratory …, 2019 - sonar.ch
METHODS RISE-IIP was a double-blind, randomised, placebo-controlled study done at 65
pulmonary hypertension and interstitial lung disease centres in 19 countries to evaluate the …

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

SD Nathan, J Behr, HR Collard… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

SD Nathan, J Behr, HR Collard, V Cottin… - The Lancet …, 2019 - europepmc.org
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …